|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Are we giving biologics too late? The case for early versus late use显示文摘Corticosteroids and immunomodulators have been the mainstay therapies for Crohn’s disease. Corticosteroids are highly effective to control symptoms in the short- term, but they are not effective in maintaining remission, they heal the mucosa in a reduced proportion of cases, and long-time exposure is associated with an increased risk of infections and mortality. Immunomodulators, azathioprine and methotrexate, heal the mucosa in a higher proportion of patients that corticosteroids but their onset of action is slow and they benefit less than half of patients with Crohn’s disease. In the last decade, medical therapy for Crohn’s disease has experienced a remarkable change due to the introduction of biologic therapy, and particularly the use of anti-tumour necrosis factor-alpha agents. Infliximab, adalimumab, and certolizumab pegol have demonstrated efficacy for induction and maintenance of remission in active Crohn’s disease. These agents have raised the bar for what is a suitable symptomatic response in Crohn’s disease and modification of the natural history of the disease has become a major goal in the treatment of Crohn’s disease. There are several data in the literature that suggest that early use of biologic therapy and achievement of mucosal healing contribute to disease course modification. However, many questions on early biological therapy for Crohn’s disease remain still unanswered. | Elena Ricart Orlando García-Bosch Ingrid Ordás Julián Panés | 2008 | World Journal of Gastroenterology2008，14，36： | 4 |
| 2 | Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study显示文摘 | Hedy L Kindler Tatsuya Ioka Dirk J Richel Jaafar Bennouna Richard Létourneau Takuji Okusaka Akihiro Funakoshi Junji Furuse Young Suk Park Shinichi Ohkawa Gregory M Springett Harpreet S Wasan Peter C Trask Paul Bycott Alejandro D Ricart Sinil Kim Eric Van | 2011 | Lancet Oncology2011，，3： | 4 |
| 3 | Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn’s Disease显示文摘 | Ingrid Ordás Jordi Rimola Sonia Rodríguez José M. Paredes María J. Martínez-Pérez Esther Blanc Juan A. Arévalo Marta Aduna Montserrat Andreu Alexander Radosevic Anna M. Ramírez-Morros Susana Pinó Marta Gallego Aranzazu Jauregui-Amezaga Elena Ricart Julián | 2013 | Gastroenterology2013，，： | 3 |
| 4 | Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study显示文摘瞄准:与活跃类固醇依赖者 ulcerative 在病人与 10 个 granulocyteaphaeresis 会议相比评估 5 的功效。方法:在这名飞行员,未来,多集中使随机化的试用,有中等活跃的类固醇的 20 个病人 -- 依赖 ulcerative 被使随机化到 5 或 10 个 granulocyteaphaeresis 会议。主要目的是在 wk 的临床的宽恕 17。第二等的措施包括了内视镜的宽恕和类固醇消费。结果:九个病人被使随机化到 5 个 granulocyteaphaeresis 会议(组 1 ) 和 11 个病人到 10 个 granulocyteaphaeresis 会议(组 2 ) 。在 wk 17,在在组 2 的组 1 病人和 45.45% 的 37.5% 病人在临床的宽恕。临床的宽恕被内视镜的宽恕在所有情况中伴随。完成宽恕的百分之 86 个病人在 wk 是没有类固醇的 17。每日的类固醇要求在组 2 是显著地更低的。病人的 89% 在一年后续期间留在宽恕。一个严肃的不利事件不与学习治疗有关,被报导。结论:Granulocyteaphaeresis 为类固醇依赖者 ulcerative 的治疗安全、有效。在这张人口,增加 aphaeresis 会议的数字没与更高的宽恕率被联系,但是负担得起重要类固醇圆材效果。 | Elena Ricart Maria Esteve Montserrat Andreu Francesc Casellas David Monfort Miquel Sans Natalia Oudovenko Raúl Lafuente Julián Panés | 2007 | World Journal of Gastroenterology2007，13，15： | 3 |
| 5 | Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype显示文摘AIM: To examine genetic variation of nucleotide oligomerization domain 1 (NOD1 ) and NOD2 ,their respective influences on Crohn's disease phenotype and gene-gene interactions. METHODS: (ND1+326561 ) NOD1 polymorphism and SNP8,SNP12 and SNP13 of NOD2 were analyzed in 97 patients and 50 controls. NOD2 variants were determined by reaction restriction fragment length polymorphism analysis. NOD1 genotyping and NOD2 variant confirmation were performed by specific amplification and sequencing. RESULTS: The distribution of NOD1 polymorphism in patients was different from controls (P = 0.045) and not altered by existence of NOD2 mutations. In this cohort,30.92% patients and 6% controls carried at least one NOD2 variant (P < 0.001) with R702W being the most frequent variant. Presence of at least one NOD2 mutation was inversely associated with colon involvement (9.09% with colon vs 36.4% with ileal or ileocolonic involvement,P = 0.04) and indicative of risk of penetrating disease (52.63% with penetrating vs 25.64% with non-penetrating or stricturing behavior,P = 0.02). L1007finsC and double NOD2 mutation conferred the highest risk for severity of disease (26.3% with penetrating disease vs 3.8% with non-penetrating or stricturing behavior presented L1007finsC,P = 0.01 and 21.0% with penetrating disease vs 2.5% with non-penentrating or stricturing behavior carried double NOD2 mutation,P = 0.007). Exclusion of patients with NOD2 mutations from phenotype/NOD1 -genotype analysis revealed higher prevalence of 11 genotype in groups of younger age at onset and colonic location. CONCLUSION: This study suggests population differences in the inheritance of risk NOD1 polymorphism and NOD2 mutations. Although no interaction between NOD1 -NOD2 was noticed,a relationship between disease location and Nod-like receptor molecules was established. | Elisabet Cantó Elena Ricart David Busquets David Monfort Esther García-Planella Dolors González Joaquim Balanzó José L Rodríguez-Sánchez Sílvia Vidal | 2007 | World Journal of Gastroenterology2007，13，41： | 2 |
| 6 | Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening显示文摘 | Aranzazu Jauregui-Amezaga Fanny Turon Ingrid Ordás Marta Gallego Faust Feu Elena Ricart Julián Panés | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 7 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial显示文摘 | David Laharie Arnaud Bourreille Julien Branche Matthieu Allez Yoram Bouhnik Jerome Filippi Frank Zerbib Guillaume Savoye Maria Nachury Jacques Moreau Jean-Charles Delchier Jacques Cosnes Elena Ricart Olivier Dewit Antonio Lopez-Sanroman Jean-Louis Dupas F | 2012 | The Lancet2012，，9857： | 2 |
| 8 | An inflammation score is better associated with basal than stimulated surrogate indexes of insulin resistance 显示文摘 | Recasens M Lopez-Bermejo A Ricart W | 2005 | J Clin Endocrinol Metab2005，90，1： | 1 |
| 9 | Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/pheno- type to thriftiness显示文摘 | Fernandez Real J M Ricart W | 1999 | Diabetologia1999，42，11： | 1 |
| 10 | Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): A protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors显示文摘 | PAPADOPOULOS K MITA A RICART A | 2007 | Mol Cancer Ther2007，6，12： | 1 |
| 11 | From strategy to business models and to tactics显示文摘 | CASADESUS-MASANELL R RICART J E | 2010 | Long Range Planning2010，43，1： | 1 |
| 12 | An inflammation score is better associated with basal than stimulated surrogate indexes of insulin resistance显示文摘 | RECASENS M LOPEZ-BERMEJO A RICART vr ? al | 2005 | J Clin Endocfinol Metab2005，900，： | 1 |
| 13 | From strategy to business models and onto tactics显示文摘 | Casadesus-Masanell R Ricart J E | 2010 | Long Range Planning2010，43，2： | 1 |
| 14 | Multiple symmetrical lipomatosis and chronic alcoholism 显示文摘 | Grau MA Gonzalez HF Ricart EW | 1989 | An Med Interna1989，6，12： | 1 |
| 15 | Nurrsing adherence with evidence - based guidelines for preventing ventilator - associated pneumonia显示文摘 | Ricart M Lorente C Diaz E | 2003 | Crit Care Med2003，31，11： | 1 |
| 16 | How to design a winning business model显示文摘 | Casadesus-Masanell R Ricart J E | 2011 | Harvard Business Review2011，89，12： | 1 |
| 17 | Insulin resistance and inflammation in an evolutionary perspective:the contribution of cytokine genotype/phenotype to thriftiness显示文摘 | Ricart RM | 1999 | Diabetologia1999，42，： | 1 |
| 18 | Identification of substituted sites on MUC5AC mucin motif peptides after enzymatic O-glycosylation combining beta-elimination and fixed-charge derivatization 显示文摘 | Czeszak X Ricart G Tetaert D | 2002 | Rapid Commun MassSpectrom2002，16，1： | 1 |
| 19 | Operator-ori- ented CRS interpolation显示文摘 | Hoecht G Ricarte P Bergler S | 2009 | Geophysical Prospec- ting2009，57，6： | 1 |
| 20 | From Strategy to Business Models and to Tactics显示文摘 | Casadesus M Ricart J | 2010 | Long Range Planning2010，，43： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员